

# Pharmaceutical Consultant Dr. Jan Lundberg to be Featured on Close Up Radio

FORT LAUDERDALE, FL, UNITED STATES, December 10, 2024 /

EINPresswire.com/ -- Dr. Jan Lundberg, a distinguished leader in the bio-pharmaceutical industry with over four decades of experience, has embarked on a new venture as a pharmaceutical consultant. With a career that seamlessly bridged academia and industry, Lundberg is offering his wealth of expertise to drive innovation in drug discovery and development. Based in Fort Lauderdale, Florida, Lundberg is poised to provide strategic guidance to biotech firms, pharmaceutical companies, and academic institutions aiming to tackle the world's most pressing health challenges.



## A Storied Career in Science and Innovation

Born in Sweden, Jan Lundberg's journey in the sciences began during his studies in America with chemistry and psychology at Gustavus Adolphus College, Minnesota. His fascination with medicine had taken root at a young age, inspired by his uncle, who showed Jan his blood under a microscope. This early curiosity set him on a path through academia, medicine, and into the heart of pharmaceutical innovation.

Lundberg's career is marked by significant R&D leadership roles at global pharmaceutical giants AstraZeneca and Eli Lilly. His work at AstraZeneca included Brilinta, a leading prevention treatment for coronary infarction, while at Eli Lilly, he was crucial in the discovery and development of groundbreaking Mounjaro treatments for type 2 diabetes and obesity, as well as Kisunla for Alzheimers.

For his academic research, he was awarded Jahre and Fernstrom prizes. Mounjaro was awarded a 2023 Galien prize for best pharmaceutical product.

As a consultant, Lundberg's primary aim is to leverage his experience to further medical innovation. "Drug hunting," a term he uses to describe the pursuit of novel therapeutic agents, encapsulates his career-long commitment to turning scientific insights into life-changing medicines. This approach remains central to his consulting offerings, which include strategic advice on drug discovery processes, regulatory pathways, and intellectual property protection.



Lundberg is particularly enthusiastic about engaging with teams to foster creativity and leadership in pharmaceutical research. "It's about getting the best out of your people and using that collective strength to move forward," he notes. His consulting work emphasizes building strong, knowledgeable teams to navigate the complex landscape of drug discovery and development.

### Addressing Global Health Challenges

Lundberg's consulting services focus on key areas such as diabetes, Alzheimer's disease, autoimmune disorders, and cancer. He is keenly aware of the complexities involved in treating conditions like cancer, which demands personalized approaches through precision medicine. "Cancer encompasses hundreds, if not thousands, of diseases. Tailored therapies based on individual biomarkers such as genetic profiles are the future," asserts Lundberg.

His work extends to co-founding a diagnostic biotech firm, Aerocrine, and improving diagnostic methods which are critical for finding cures for diseases like Alzheimer's.

With over 500 research articles to his name, Lundberg emphasizes the importance of continuous learning and adaptation in scientific research. "Scientists need creativity and the ability to synthesize diverse sources of information," he says. He believes that keeping pace with the latest advancements is crucial for meaningful contributions to the field. Artificial Intelligence (AI) can be very helpful in this area.

Lundberg also serves on several biotech boards, utilizing his vast experience to evaluate and guide promising new programs. His consulting services integrate this strategic oversight, helping companies navigate the risks and opportunities within the ever-evolving pharmaceutical industry.

#### A Commitment to Innovation and Leadership

Jan Lundberg's consulting practice draws on his extensive history of leadership and scientific achievement. Encouraging collaboration and strategic thinking, Lundberg's services are a vital resource for organizations seeking to bring innovative treatments to market.

After retiring from Eli Lilly, Lundberg enjoys the sun-drenched lifestyle of Fort Lauderdale, mixed with outdoor activities in Jackson Hole, Wyoming yet maintains strong professional connections with both Sweden and the global scientific community. He remains deeply committed to harnessing scientific creativity to improve health outcomes worldwide.

Close Up Radio will feature Jan Lundberg of Lundberg Bio Pharmaceuticals in an interview with Jim Masters on Thursday, December 12th at 3pm EST

Listen to the show on [BlogTalkRadio](#)

If you have questions for our guest, please call (347) 996-3389

For more information about Jan Lundberg, please visit <https://www.linkedin.com/in/jan-m-lundberg-77729a95/>

Lou Ceparano

Close Up Television & Radio

+1 631-850-3314

[email us here](#)

Visit us on social media:

[Facebook](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/767792236>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.